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Abstract
Background: A key advantage of monitoring HIV viral load (VL) in persons receiving antiretroviral therapy (ART) is the ability
to detect virologic failure before clinical deterioration or resistance occurs. Detection of virologic failure will help clarify the
need for enhanced adherence counseling or a change to second- line therapy. Low-cost, locally performable alternates to
expensive VL assays are needed where resources are limited.
Methodology/Principal Findings: We monitored the response to 48-week ART in 100 treatment-naı ¨ve Kenyan adults using
a low-cost VL measurement, the Cavidi reverse transcriptase (RT) assay and gold-standard assays, Roche RNA PCR and Bayer
Versant HIV-1 RNA (bDNA) assays. In Altman-Bland plots, the mean difference in viral loads between the three assays was
small (,0.5 log10 copies/mL). However, the limits of agreement between the methods exceeded the biologically relevant
change of 0.5 log copies/ml. Therefore, the RT assay cannot be used interchangeably with the other assays to monitor
individual patients. The RT assay was 100% sensitive in detecting viral loads of $400 copies/ml compared to gold-standard
assays. After 24 weeks of treatment, viral load measured by the RT assay was undetectable in 95% of 65 patients with
undetectable RNA PCR VL (,400 copies/ml), 90% of 67 patients with undetectable bDNA VL, and 96% of 57 patients with
undetectable VL in both RNA PCR and bDNA assays. The negative predictive value of the RT assay was 100% compared to
either assay; the positive predictive value was 86% compared to RNA PCR and 70% compared to bDNA.
Conclusion: The RT assay compared well with gold standard assays. Our study highlights the importance of not
interchanging viral load assays when monitoring an individual patient. Furthermore, the RT assay may be limited by low
positive predictive values when used in populations with low prevalence of virologic failure.
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Introduction
An estimated 3 million HIV-infected patients in low- and
middle-income countries were receiving antiretroviral therapy at
the end of 2007 [1]. As the number of treated persons increases, so
will the number failing treatment. World Health Organization
(WHO) guidelines acknowledge the need to diagnose treatment
failure using only clinical and/or CD4 T-cell criteria because high
cost precludes the use of viral load assays in resource-limited
settings (RLS) [2]. However, clinical and immunologic markers are
poor predictors of virologic suppression [3,4]. Furthermore, viral
replication can increase months before immunologic or clinical
deterioration, leading to resistance mutations that may limit future
treatment options [5,6]. Because, poor treatment adherence is the
major cause of treatment failure of first-line HIV regimens [7],
viral load measurements can help identify patients who might
benefit from intensive adherence counseling and thus prevent, or
at least postpone, a change to second-line therapy[8]. Despite
these benefits, viral load monitoring remains inaccessible to the
majority of patients on ART in RLS [9,10].
One alternative to directly measuring the number of HIV RNA
copies is to estimate it by measuring the activity of the HIV virus-
encoded reverse transcriptase enzyme (RT) using the Cavidi
ExaVir
H reverse transcriptase assay, a commercially available kit
that is already used in some African countries. While gold-
standard viral load assays such as Roche Amplicor HIV-1 Monitor
(RNA PCR) and Bayer Versant HIV-1 RNA (bDNA) may cost
,$80 per test, the RT assay costs approximately $21 dollars in
Kenya. The equipment required for the RT assay is minimal and
the assay can be conducted in a district- or provincial-level
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6828laboratory [11,12]. An agreement signed in 2007 between Cavidi
Tech and the Clinton Foundation to further reduce the cost of this
assay to $12.50 per test will only increase its use (Fabio Baglioni,
personalcommunication;Alsosee:http://www.cavidi.se/Templates/
Cavidi/FileService.axd?id=38&v=1).
The RT assay has not been evaluated in a longitudinal field trial
for monitoring patients on ART in RLS. Therefore, we monitored
HIV-infected Kenyan adults initiating ART for 48 weeks using the
RT assay, the RNA PCR, and the bDNA assays.
Methods
Study site
The study was conducted at the Bomu Medical Center (BMC),
a non-governmental outpatient clinic located in an urban slum in
Mombasa, Kenya. Since 2004, New York University School of
Medicine has received funding from the Presidential Emergency
Plan for AIDS Relief (PEPfAR) to provide free HIV care to
patients attending BMC. ART treatment initiation criteria were
CD4 count ,200 cells/mL or WHO stage III or IV, irrespective of
CD4 T-cell count [2]. The first line treatment regimen was the
combination of stavudine (d4T), lamivudine (3TC), plus either
nevirapine (NVP) or efavirenz (EFV). Zidovudine (AZT), didan-
osine (ddI) and lopinavir/ritonovir (Kaletra) were available for
patients with drug toxicities or treatment failure.
One hundred consecutive ART-naı ¨ve patients were enrolled
into the study if they were eligible to start ART and all provided
written informed consent. The institutional review boards at
Kenyatta National Hospital and at New York University School of
Medicine approved this study.
Study visits occurred from 2004 through 2006, at baseline (before
first ART dose) and weeks 4, 12, 24, 36 and 48. Each patient reported
the number of doses of ART missed since the last visit. Perfect
adherence was defined as reporting no missed doses since the last visit.
Table 1. Baseline characteristics of study participants.
Baseline Characteristic
a Value
b
Female sex—no. (%) 69 (69)
Age—no.(%)
,10 2 (2)
11–19 0 (0)
20–29 32 (32)
30–39 43 (43)
40–49 28 (28)
.49 4 (4)
Ethnicity/Tribe –no.(%) (N=96)
Kamba 18 (19)
Luo 16(17)
Luhya 13(14)
Kikuyu 11(11)
Other (representing 18 different tribes) 38 (40)
Religion—no.(%) (N=99)
Christian 79(80)
Muslim 20(20)
Education—no.(%) (N=94)
None 9(10)
Primary school 41(44)
Secondary school 39(41)
College 5(5)
Marital status—no.(%) (N=96)
Married 48(50)
Divorced/separated 20(21)
Single 14(15)
Widowed 14(15)
Occupation—no.(%) (N=97)
Unemployed 41(42)
Small business 28(29)
Skilled manual labor 14(14)
Professional 8(8)
Unskilled manual labor 6(6)
Able to read –no.(%) (N=96) 86(90)
Able to write –no.(%) (N=96) 87(91)
Number of years between HIV diagnosis and
initiating antiretroviral therapy—no.(%) (N=97)
#1 year 72(74)
2 years 15(15)
3–5 years 8(8)
.5 years 2(2)
WHO Stage—no. (%)
I 14(14)
II 23(23)
III 62(62)
IV 1(1)
Tuberculosis—no.(%) 9 (9)
Pneumonia—no.(%) 7(7)
Diarrhea—no (%) 25(25)
Baseline Characteristic
a Value
b
Received anti-malaria medication 1 month prior to
initiating antiretroviral therapy—no. (%)
36 (36)
Pregnant—no.(%) N=67 6(9)
CD4 T-cell count—per mm
3
Median 147
Interquartile range 61–197
HIV viral load (RNA PCR) copies/ml
Median 204,500
Interquartile range 95,175–651,000
Hemoglobin—g/dl
Median 10.6
Interquartile range 9.5–11.4
Initial antiretroviral-therapy regimen—no.(%) N=93
c
Stavudine, lamivudine, efavirenz 53 (57)
Stavudine, lamivudine, nevirapine 33 (36)
Zidovudine,lamivudine,nevirapine 7 (8)
aN=100 unless otherwise noted.
bTotals may not add to 100 because of rounding.
cSeven patients were lost to follow-up before treatment could be started.
doi:10.1371/journal.pone.0006828.t001
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on plasma samples stored at 280uC. Viral load measurements were
conducted on a single plasma sample that underwent a single thaw
prior to testing. The Roche Amplicor HIV-1 Monitor Test, v1.5.
(Roche Molecular Systems, Branchburg, NJ) procedure was
performed, in blinded fashion, at the Kenya Medical Research
Institute, according to the manufacturer’s instructions [13].
Reported values for the Upper Limit of Quantitation (ULQ) and
the Lower Limit of Quantitation (LLQ) were 750,000 (5.9 log10)
copies/ml and 50 (1.7 log10) copies/mL, respectively. The
VERSANT HIV-1 RNA 3.0 assay (Bayer Diagnostics, Tarrytown,
NY) was performed at BMC according to the manufacturer’s
instructions by a technician trained by Bayer Diagnostics [14,15].
The ULQ for this assay is 500,000 (5.7 log10) copies/ml, and the
LLQ is75(1.9log10) copies/mL.Duetoa technical errorinone run,
nine samples for the bDNA assay were excluded from the analysis.
The Cavidi ExaVir
H Load Reverse Transcriptase Assay, version
2 assay was conducted in a blinded fashion according to the
manufacturer’s directions by Chem-Labs in Nairobi, the reference
laboratory for Cavidi. Briefly, interfering enzymes in plasma were
inactivated, virus was captured on a separation gel, drugs and
other inhibitors washed away, and virions lysed to recover virion-
associated RT enzyme. RT activity was measured by the
enzymatic incorporation of bromdeoxyuridine (BrdU) into DNA
captured on a poly-A coated enzyme immunoassay (EIA) plate,
and the amount of incorporated BrdU was quantified by
colorimetric detection. The results were calculated using the
ExaVir
H Load Analyzer software and expressed in femtogram/ml
Figure 1. Flow chart of subjects with HIV viral loads conducted at baseline and follow-up after 24 weeks of antiretroviral therapy.
(RT=Cavidi reverse transcriptase (RT) assay, Roche RNA PCR, and bDNA=branched DNA assay).
doi:10.1371/journal.pone.0006828.g001
Table 2. Characteristics of the Cavidi
H reverse transcriptase assay for detecting HIV viral loads $400 copies/mL using RNA PCR or
branched DNA assay (bDNA) assays in patients receiving antiretroviral therapy.
Detecting HIV RNA PCR $400 copies/mL Detecting bDNA $400 copies/mL
Sensitivity % (95% CI
a)
b 100 (96–100) 100 (96–100)
Specificity % (95% CI)
b 95 (87–98) 90 (80–95)
Positive Predictive Value
c % (95% CI) 86 (65–95) 70 (49–84)
Negative Predictive Value
c % (95% CI) 100 (94–100) 100 (94–100)
a95% CI, 95% Confidence Interval.
bSensitivity of the RT assay was the proportion of patients at baseline with RT assays $400 eq copies/ml among those with viral loads $400 copies/ml using RNA PCR
or bDNA assays. Specificity of the RT assay was the proportion of patients at week 36 or 48 of treatment (which ever was the last value) with undetectable RT activity
among those with viral loads ,400 copies/ml using RNA PCR or bDNA assays. bDNA data from nine patients were excluded due to technical errors in one run.
cPositive and negative predictive values were calculated using a 22% prevalence (18 of 83 patients with RNA PCR available after week 24) of a detectable RNA PCR viral
load at week 36 or 48 of therapy; a sensitivity of 100% and specificity of 95% for the RNA PCR assay and a sensitivity of 100% and a specificity of 90% for the bDNA
assay.
doi:10.1371/journal.pone.0006828.t002
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for this assay varied in each run and ranged from 400,000 to
970,000 copies/mL, and the LLQ is 400 copies/ml.
Laboratory measurements included CD4 T-cell count, complete
blood count, blood electrolytes, and liver function tests. CD4 cell
counts were measured using Partec-GmBH (Partec, Mu ¨nster,
Germany) and FACSCount (Becton Dickinson Immunocytometry,
Oxford, UK). No external quality assurance program was in place
for either type of CD4 cell count instrumentation because this
technologyhadbeenonlyrecentlyintroducedtotreatmentprograms
in Kenya. Twenty-seven patients did not have a CD4 cell count
determination made after 24 weeks for the following reasons: 17
patients either died, were lost to follow-up or transferred to another
institution and 10 patients either did not have CD4 counts ordered
by the physician or there was insufficient blood volume. There was
no statistically significant difference in terms of baseline CD4 cell
count, baseline viral load, age, sex, or virologic failure between
patients who did and did not have week 36 or 48 CD4 count.
Statistical analysis
Although the lower limit of detection is different in the three
viral load assays, we defined a ‘‘detectable viral load’’ as
$400 copies/ml and ‘‘undetectable viral load as ,400 copies/
ml for all three assays. Sensitivity of the RT assay was the
proportion of patients at baseline with detectable viral loads using
the RT assay among those with detectable viral loads using RNA
PCR or bDNA assays. Specificity of the RT assay was the
proportion of patients after week 24 with undetectable RT activity
among those with undetectable viral loads using RNA PCR or
bDNA assays. The RT and RNA PCR or bDNA assays were
compared using the Spearman correlation coefficient and the
Altman-Bland plot [16]. The ability of the RT assay to
differentiate between those with and without detectable RNA
PCR viral load after week 24 was evaluated using the receiver
operator characteristic (ROC) curve.
At 48 weeks, we defined the status of each patient as ‘‘in study,’’
‘‘deceased,’’ ‘‘lost to follow-up’’ (missed 2 or more consecutive
Figure 2. The measure of agreement between the RT assay and RNA PCR or bDNA assays is shown in the Altman-Bland plots. A. RT
assay (equivalent log10 copies/ml) and RNA assay (log10 copies/ml); B. RT assay (equivalent log10 copies/ml) and bDNA assay (log10 copies/ml); and C.
RNA assay (log10 copies/ml) and bDNA assay (log10 copies/ml). The dotted line represents the mean difference between values. Solid lines represent
two standard deviations (2SD) (95% limits of agreement).
doi:10.1371/journal.pone.0006828.g002
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‘‘Immunologic failure’’ was defined as a) a fall of CD4 count to
pre-therapy level or b).50% fall from the on-treatment peak, or c)
a persistent CD4 level below 100 cells/ml [2]. ‘‘Virologic failure’’
was defined as either a) plasma RNA PCR viral load $400 cop-
ies/ml on two consecutive measurements after 24 weeks of
therapy, following at least one undetectable viral load (,400
copies) after initiating ART or b) never achieving a RNA PCR
viral load ,400 copies/ml [2]. Values above the cut-off
($400 copies/ml) were log10 transformed for analysis.
X
2 and Fisher’s exact tests were used to compare categorical data
and Student’s t test was used to compare continuous variables. P
values of ,0.05 were considered to be statistically significant.
Logistic regression was used to model variables associated with
undetectable RNA PCR viral load. Patients who died, were lost to
follow-up or transferred to another institution before the end of the
study were not included in this analysis. Analyses were conducted
using SPSS, version 11(SPSS Inc., Chicago, IL).
Results
The median age of the 100 patients was 35 years (range, 5–68); 69
(69%)werewomen(Table1)andthemedianbaselineCD4cellcount
was 147 cells/ml. Seventy-two (74%) of 97 patients who initiated
ART, did so #1 year after HIV diagnosis. At week 48, 80 (80%)
patients remained in care, 7 (7%) had died, 9 (9%) were lostto follow-
up, and 4 (4%) transferred to another institution. Women were more
likely to have remained in care (P=0.03). Otherwise, baseline
characteristics (CD4 cell count, RNA PCR viral load, and age) did
not differ between patients who remained in the study and those who
did not. Among the seven patients who died, five died within 12
weeks after initiating therapy and two between 12 and 36 weeks.
Comparison between the RT, RNA PCR and bDNA assays
At baseline, 97 (97%) of 100 persons had detectable viral load
by RNA PCR and 88 (99%) of 89 persons had detectable viral
load by bDNA assay. Data from nine persons were excluded
because of technical error in one bDNA assay run and two persons
did not have sufficient sample volume to conduct all three assays at
baseline (Figure 1). The sensitivity of the RT assay relative to the
HIV RNA assay was 100% (97 of 97 patients with RNA PCR viral
loads $400 copies/ml had detectable RT activity). The sensitivity
of the RT assay relative to bDNA assay was 100% (88 of 88
patients with detectable viral loads measured by bDNA had
detectable RT activity) (Table 2).
The specificity of the RT assay was 95% compared to the RNA
PCR assay (62 of 65 patients with RNA PCR viral loads
,400 copies/ml had undetectable RT activity) and 90% com-
pared to the bDNA assay (60 of 67 patients with undetectable viral
loads had undetectable RT activity). Among the 83 patients tested
after 24 weeks of treatment, in eight, viral load was undetectable
using the RT assay but detectable using either the RNA or bDNA
assays. Five of the eight samples were RNA positive but bDNA
negative, one was RNA negative but bDNA positive and two were
negative in both RNA and bDNA assays. Therefore, the specificity
of the RT assay was 96% compared to both RNA and bDNA
assays (55 of 57 patients with both RNA PCR and bDNA viral
loads ,400 copies/ml had undetectable RT activity).
Correlations between RT and RNA PCR assays and RT and
bDNA assays were statistically significant (Spearman correlation
coefficients: 0.77, P,0.00001, and 0.66, P,0.00001, respectively).
Themeasureofagreementbetween the RTassayandRNAPCRor
bDNA assays is shown in the Altman-Bland plots in Figure 2.
Because these plots visually assess the average difference in values
between two assays over the usable range of the assays, only patients
Figure 3. The proportion of patients with a detectable viral load ($400 copies/ml) at study visits using three viral load assays
(Cavidi reverse transcriptase (RT) assay, Roche RNA PCR, and branched DNA assay [bDNA]).
doi:10.1371/journal.pone.0006828.g003
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The mean difference between RT and RNA PCR assays was 0.09
log copies (95% CI: 20.008, 0.19) and the 95% limits of agreement
(Mean+2SD, Mean - 2SD) were 1.32 log copies and 21.13 log
copies. The mean difference between RT and bDNA assays was
0.45logcopies(95%CI:0.35,0.54)and thelimitsofagreementwere
1.51 and 20.61 log copies. The mean difference between RNA and
bDNA assays was 0.26 log copies (95%CI: 0.12, 0.40) and the limits
of agreement were 1.96 and 21.44 log copies.
The areaunder the ROC curve was0.89(95% CI, 0.78–1.00) for
identifying patients with virologic failure using the RT assay. The
optimal inflection point was located at an RT viral load cut-off of
,750 copies/ml (true positive rate: 90%; false positive rate: 8%).
Virologic, immunologic and clinical response to ART
The median baseline RNA PCR viral load was 204,500 copies/
ml (5.3 log10 copies). Six patients did not have a follow-up viral
load after the baseline visit, and eleven did not have a follow-up
viral load after week 24. At week 48 of treatment, 18% of patients
had a single detectable viral load ($400 copies/ml) using the
bDNA and RT assays and 22% using the RNA PCR assay
(Figure 3). When defining virologic failure as having two
consecutive viral loads $400 copies/ml, among 83 patients who
had viral load measurements conducted after 24 weeks of therapy,
10 (12%) had virologic failure; three never attained a viral load
,400 copies/ml; three failed at 24 weeks and four at 36 weeks.
The median RNA PCR viral load at the time of failure was
5,990 copies/ml (IQR: 1,540–287,250). In univariate analysis,
patients with virologic failure were younger (32 years vs 35 years;
P=0.03) and were more likely to have imperfect adherence (OR
5.16, (95% CI: 1.20–22; P=0.03) (Table 3).
The median increase in CD4 T-cell count was 130 cell/mm
3
(IQR,34–247)(Figure4).Seventy-threepatientshad CD4cellcount
available at baseline and after week 24 of treatment. Eighteen
patientshadimmunologicfailurewhileontreatment;fourteen(78%)
of these 18 patients had virologic suppression using RNA PCR.
Discussion
We describe a longitudinal study of virologic treatment response
to ART among antiretroviral-naı ¨ve Kenyan adults. Many received
HIV testing late in their disease as demonstrated by the fact that
74% of those requiring ART were diagnosed within the prior year.
The virologic failure rate, defined as a detectable RNA viral load
on two consecutive measurements after 24 weeks of treatment, was
12%, with younger age and imperfect adherence being significant
risk factors for failure. A wide range of virologic failure rates are
reported from RLS, ranging from 4%–36%, in part because
of the use of inconsistent definitions of virologic failure
[17,18,19,20,21,22,23,24,25,26]. We used a conservative defini-
tion of virologic failure, requiring two consecutive measurements
of $400 copies/ml to avoid misclassifying intra-individual varia-
tions, laboratory errors, or transient elevations due to illnesses as
true virologic failures.
The mean difference in viral loads between the RT assay, RNA
PCR and bDNA assays as shown in the Altman-Bland plot was
small (,0.5 log10 copies/ml) and did not vary systematically over
the range of the assays. However, because the limits of agreement
between the methods exceeded what is considered a biologically
relevant change of 0.5 log copies/ml [27], we conclude that the
RT assay cannot be used interchangeably with the RNA PCR or
the bDNA assays. This caveat is also known to apply to the two
gold standard viral load assays, and has led to the recommenda-
tion that a single assay be used to monitor treatment response in
an individual patient in resource-rich countries [27]. Similar
precautions will be even more relevant in RLS since HIV
treatment programs may begin to offer viral load testing from
different laboratories using different viral load technologies due to
overwhelmed central laboratories.
Several studies have compared the ExaVir
H RT V.2 assay to gold
standard viral load assays, however none was longitudinal
[28,29,30,31]. RT enzyme activity was detected in 95%–100% of
samples having RNA PCR viral loads $50 copies/mL[31],
$500 copies/mL [30], $1,000 copies/mL[28], and $2,000 cop-
ies/mL[29], and performed well for non-clade B HIV subtypes [29].
In our study, 95% of 65 patients with RNA PCR viral loads
,400 copies/ml also had undetectable RT activity, while 97% of 65
patients with undetectable viral loads in both the RNA PCR and
bDNA assays had undetectable viral load. Similarly, a study
conducted in Botswana reported a specificity of 98% compared to
RNA PCR [12]. In contrast, a recent study conducted in Kenya
reported that only 12 (38%) of 31 samples with undetectable virus by
RNA PCR had undetectable RT activity [31]. False-positive results
given by the RT assay may indicate a lack of specificity of the test or
laboratory error. An alternate possibility is that because the RT assay
detectsenzyme activity and therefore is not HIV sequence dependent,
in contrast to gold-standard assays, false-positive results may actually
indicateincreasedsensitivityoftheRTassayindetectingrecombinant
Table 3. Characteristics associated with HIV RNA PCR
virologic failure for antiretroviral naı ¨ve patients receiving
antiretroviral therapy (ART), Mombasa, Kenya.
a
Predictor variables Univariate analysis
OR
b (95% CI) P
Age – 0.03
c
Sex
Male Ref
Female 3.95 (0.47–32) 0.20
Pregnant
No Ref
Yes 3.78 (0.58–24.6) 0.16
WHO Stage
Stage 1 or 2 Ref
Stage 3 or 4 1.16 (0.30–4.4) 0.83
Highest level of education
Primary school or none Ref
Secondary school or higher 2.71 (0.63–11.6) 0.18
Occupation
Unemployed Ref
Employed 1.09 (0.28–4.1) 0.91
Adherence
Perfect Adherence Ref
Imperfect Adherence 5.16 (1.2–22) 0.03
Baseline CD4 cell count
,200 cells/ml Ref
$200 cells/ml 1.78 (0.40–7.8) 0.45
aExcludes patients who died, were lost to follow up or transferred care to
another institution.
bOR, Odds Ratio; CI, Confidence interval.
cBy Student’s t test.
doi:10.1371/journal.pone.0006828.t003
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based assays. Since clade typing was not conducted in this study this
remains a hypothesis. However, the potential for false-positive results
using any of these assays warrants caution in using a single viral load
measurement to trigger switch to second-line regimens.
Cost-effectiveness studies have shown that adding viral load
monitoring is not cost-effective when second-line therapy is not
available[32], but is cost-effective when second-line regimens are
available [10,33]. Furthermore, the cost-effectiveness ratio de-
pends greatly on the viral load test price[10,33] and rates of
virologic failure[10]. In a recent South African study, in which the
authors assumed that a single viral load of .1,000 copies/ml led
to a switch to second-line therapy, reducing the per test cost of the
viral load assay from $80 to $20 decreased the incremental cost-
effectiveness ratio (ICER) from approximately $5,000 to $1,635
[10]. Interventions with an ICER between 1 and 3 times the gross
domestic product (GDP) per capita are considered cost-effective,
therefore extrapolating to Kenya ($1,600 GDP per capita in 2007),
use of the RT assay (costing approximately $20 per test) would be
considered a cost-effective intervention. The price of the RT assay
is expected to decrease to $12.50 per test (personal communica-
tion, Fabio Baglioni, Cavidi AB) thereby further increasing the
cost-effectiveness of this assay.
Many cost-effectiveness studies assume that a single high viral
load would automatically trigger a switch to the more expensive
second-line regimen[9,10,33]. This assumption likely drives up the
cost of the viral load monitoring strategy unnecessarily. Programs
have shown that viral load monitoring may, in fact, help to
preserve first-line regimens through intensified adherence coun-
seling [8,34,35]. Therefore, cost-effectiveness studies that include
other consequences of monitoring viral loads in patients receiving
ART, such as more intensive adherence counseling leading to
better adherence and therefore fewer switches to second line
regimen, may provide a more realistic cost of viral load monitoring
in RLS.
Aside from cost, another advantage of the RT assay is that it
does not require specialized laboratories or equipment and
therefore can be conducted in a district or provincial laboratory,
rather than a central laboratory [12]. Centralization of laboratory
testing adds significant complexity and expense; increases
Figure 4. The distribution of CD4 cell count and HIV viral loads since initiation of antiretroviral therapy (study week 0). A.
Distribution of CD4 cell count; B. HIV viral load by RNA PCR; C. HIV viral load by branched DNA (bDNA) assay; D. HIV viral load by Cavidi reverse
transcriptase (RT) assay. Top and bottom of the boxes are 25th and 75th percentiles, respectively. Horizontal lines within the boxes indicate median
values. Central vertical lines (whiskers) that extend from the boxes to the highest and lowest rates indicate the 95% and 5%, respectively. Dots
indicate the individual values outside whiskers.
doi:10.1371/journal.pone.0006828.g004
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patient identifiers and results; and increases turn-around times
when testing volume is high. Although the three day turn-around
time for the RT assay is often cited as a limitation of the
assay[11,12], in reality, sending samples to a central laboratory for
viral load testing will likely result in longer turn-around times
between collecting the sample and getting the test result because of
various delays in shipping, sample processing and reporting.
There were several limitations to this study. Two different
instruments in different laboratories were used to measure the
CD4 cell count. This compromises the estimation of immunologic
failure through changes in CD4 cell counts. However, previous
studies substantiate our finding that using immunologic criteria to
predict virologic failure is problematic [3,4,36]. External quality
assurance programs were not available for the viral load assays.
However all assays were performed using internal controls and by
technicians trained by the manufacturer for the purpose of the
study (bDNA) or in reference laboratories (RT assay and RNA
PCR). Small sample size resulted in wide confidence intervals for
the PPV therefore larger studies may be warranted before wide
implementation of this assay is recommended. Finally, our study
only included treatment-naı ¨ve patients. We cannot readily
extrapolate the performance characteristics of the RT assay found
in our study to treatment-experienced patients who may be
infected with viruses with heavily mutated RT enzymes. Although
preliminary data do not raise significant concerns [28], additional
studies of the RT assay for monitoring treatment-experienced
patients will be important.
Clearly defined strategies on the use of viral load monitoring
technologies in RLS are not currently available and many
questions remain, including whether viral load monitoring is even
necessary [10,37]. Access to a lower-cost assay that can be
conducted in a district or provincial level laboratory is the first step
to wider access to viral load monitoring. Overall, we found the RT
assay compared well with gold standard assays in monitoring viral
load responses to ART over 48 weeks making it a promising test
for use in RLS.
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